type 1 member 3 taste receptor binding

description: Binding to a type 1 member 3 taste receptor.


myosin VI light chain binding

category: biolink:MolecularActivity biolink:Occurrent biolink:OntologyClass biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing biolink:PhysicalEssenceOrOccurrent

description: Binding to a light chain of a myosin VI complex.


endocytic targeting sequence binding

description: Binding to a endocytic signal sequence, a specific peptide sequence, of 4-6 amino acids with an essential tyrosine (Y), found on cytoplasmic tails of some cell surface membrane proteins, which directs internalization by clathrin-coated pits.


MATH domain binding

description: Binding to a meprin and TRAF homology (MATH) domain.


name: intercellular adhesion molecule-3 receptor binding

description: Binding to a receptor for intercellular adhesion molecule-3 (ICAM-3), such as DC-SIGN and LFA-1.


name: cell adhesive protein binding involved in AV node cell-bundle of His cell communication

description: Binding to a protein or protein complex that results in the connection of an AV node cell with a bundle of His cell and contributes to the communication between the two cells.


H2 histamine receptor binding

description: Binding to a H2 histamine receptor.


corazonin receptor binding

description: Binding to a corazonin receptor.


myosin VI heavy chain binding

description: Binding to a heavy chain of a myosin VI complex.


MH2 domain binding

description: Binding to a MH2 (MAD homology 2) protein domain. The MH2 domain is found at the carboxy-terminus of MAD related proteins such as Smads. The MH2 domain mediates interaction with a wide variety of proteins and provides specificity and selectivity to Smad function and also is critical for mediating interactions in Smad oligomers.


RIP homotypic interaction motif binding

description: Binding to a RIP homotypic interaction motif (RHIM) of a protein. The RHIM is a 16-amino-acid motif found in some members, including RIP3, of a family of related kinases.


interleukin-10 binding

description: Binding to interleukin-10.


ErbB-4 class receptor binding

description: Binding to the protein-tyrosine kinase receptor ErbB-4/HER4.


V1B vasopressin receptor binding

description: Binding to a V1B vasopressin receptor.


MADS box domain binding

description: Binding to a MADS box domain, a protein domain that encodes the DNA-binding MADS domain. The MADS domain binds to DNA sequences of high similarity to the motif CC[A/T]6GG termed the CArG-box. MADS-domain proteins are generally transcription factors. The length of the MADS-box is in the range of 168 to 180 base pairs.


type 1 member 1 taste receptor binding

description: Binding to a type 1 member 1 taste receptor.


low molecular weight kininogen binding

description: Binding to a kininogen of low molecular mass.


type 7 serotonin receptor binding

description: Binding to a type 7 serotonin receptor.


neuropeptide F receptor binding

description: Binding to a neuropeptide F receptor.


acetylation-dependent protein binding

description: Binding to a protein upon acetylation of the target protein.


CRD domain binding

description: Binding to a CRD (context dependent regulatory) domain, a domain of about 130 residues that is the most divergent region among the LEF/TCF proteins.


nuclear cortisol receptor binding

description: Binding to a nuclear cortisol receptor.


name: DNA-binding transcription factor binding

description: Binding to a DNA-binding transcription factor, a protein that interacts with a specific DNA sequence (sometimes referred to as a motif) within the regulatory region of a gene to modulate transcription.


chemokine (C-C motif) ligand 12 binding

description: Binding to chemokine (C-C motif) ligand 12.


type 4 neuropeptide Y receptor binding

description: Binding to a type 4 neuropeptide Y receptor.


linear polyubiquitin binding

description: Binding to a linear polymer of ubiquitin. Linear ubiquitin polymers are formed by linking the amino-terminal methionine (M1) of one ubiquitin molecule to the carboxy-terminal glycine (G76) of the next.


prostaglandin F2-alpha receptor binding

description: Binding to a prostaglandin F2-alpha receptor.


farnesylated protein binding

description: Binding to a farnesylated protein.


name: pituitary adenylate cyclase-activating polypeptide receptor binding

description: Binding to a pituitary adenylate cyclase-activating polypeptide receptor.


name: gastric inhibitory polypeptide receptor binding

description: Binding to a gastric inhibitory polypeptide receptor.


myosin II head/neck binding

description: Binding to the head/neck region of a myosin II heavy chain.


type-II dockerin domain binding

description: Binding to a type-II dockerin domain of a protein. Type-II dockerin domain is the binding partner of type-II cohesin domain.


interleukin-17 binding

description: Binding to a member of the interleukin-17 family of cytokines.


name: laminin binding involved in cell-matrix adhesion

description: Any laminin protein binding that occurs as part of cell-matrix adhesion.


name: orexigenic neuropeptide QRFP receptor binding

description: Binding to an orexigenic neuropeptide QRFP receptor.


gonadotropin-releasing hormone binding

description: Binding to gonadotropin-releasing hormone (GnRH), a peptide hormone responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. GnRH is synthesized and released by the hypothalamus.


A3 adenosine receptor binding

description: Binding to an A3 adenosine receptor.


name: poly-ADP-D-ribose modification-dependent protein binding

description: Binding to a protein upon poly-ADP-ribosylation of the target protein.


subtype 3 bombesin receptor binding

description: Binding to a subtype 3 bombesin receptor.


thioglucosidase binding

description: Binding to a thioglucosidase enzyme.


Krueppel-associated box domain binding

description: Binding to a Krueppel-associated box (KRAB) domain of a protein. The approximately 75 amino acid KRAB domain is enriched in charged amino acids, and is found in the N-terminal regions of many zinc finger-containing transcription factors.


Rel homology domain binding

description: Binding to a Rel Homology Domain (RHD) of a protein. The RHD is found in a family of eukaryotic transcription factors, which includes NF-kappaB, Dorsal, Relish and NFAT.


urea binding

description: Binding to urea, a water-soluble carboxamide with the structure H2N-CO-NH2.


oxytocin receptor binding

description: Binding to an oxytocin receptor.


kisspeptin receptor binding

description: Binding to a kisspeptin receptor.


type 1D serotonin receptor binding

description: Binding to a type 1D serotonin receptor.


H3K27me3 modified histone binding

description: Binding to a histone H3 in which the lysine residue at position 27 has been modified by trimethylation.


high mobility group box 1 binding

description: Binding to high mobility group box 1 (HMBGB1).


UFM1-modified protein reader activity

description: A molecular adaptor recognizes and binds a target protein containing a UFM1 modification and brings the target protein into contact with another protein to allow those proteins to function in a coordinated way.


adrenomedullin receptor binding

description: Binding to an adrenomedullin receptor.


name: type 1 melanin-concentrating hormone receptor binding

description: Binding to a type 1 melanin-concentrating hormone receptor.


LEM domain binding

description: Binding to a LEM domain. The LEM domain (for lamina-associated polypeptide, emerin, MAN1 domain) is present in a group of nuclear proteins that bind chromatin through interaction of the LEM motif with the conserved DNA crosslinking protein, barrier-to-autointegration factor (BAF).


syntaxin-3 binding

description: Binding to a syntaxin-3 SNAP receptor.


name: thyrotropin-releasing hormone receptor binding

description: Binding to a receptor for thyrotropin-releasing hormone, a tripeptide hormone that is produced by the hypothalamus and stimulates the release of thyroid-stimulating hormone (TSH) and prolactin by the anterior pituitary.


CAP-Gly domain binding

description: Binding to a CAP-Gly domain of a protein. The CAP_Gly domain is a conserved, glycine-rich domain of about 42 residues found in some cytoskeleton-associated proteins, and features a novel protein fold containing three beta-sheets.


name: MHC class I protein binding, via lateral surface

description: Binding to a major histocompatibility complex class I molecules via the lateral surface.


EGF repeat binding

description: Binding to Epidermal Growth Factor (EGF) repeats.


name: type 2 vasoactive intestinal polypeptide receptor binding

description: Binding to a type 2 vasoactive intestinal polypeptide receptor.


name: type 5 metabotropic glutamate receptor binding

description: Binding to a type 5 metabotropic glutamate receptor.


interleukin-25 binding

description: Binding to interleukin-25.


cannabinoid receptor binding

description: Binding to a cannabinoid receptor.


name: cell adhesive protein binding involved in SA cardiac muscle cell-atrial cardiac muscle cell communication

description: Binding to a protein or protein complex that results in the connection of an SA cardiomyocyte with an atrial cardiomyocyte and contributes to the communication between the two cells.


P2Y2 nucleotide receptor binding

description: Binding to a P2Y2 nucleotide receptor.


SMC family protein binding

description: Binding to a protein from the structural maintenance of chromosomes (SMC) family, a group of chromosomal ATPases with a role in mitotic chromosome organization.


AF-1 domain binding

description: Binding to an AF-1 protein domain, a ligand-independent transactivation domain which is required for the full transcriptional activity of the receptor.


type 5 somatostatin receptor binding

description: Binding to a type 5 somatostatin receptor.


CD70 receptor binding

description: Binding to a CD70, a receptor found on the surface of most activated B cells and some activated T cells.


name: imaginal disc growth factor receptor binding

description: Binding to an imaginal disc growth factor receptor.


neuregulin binding

description: Binding to a neuregulin, a member of the EGF family of growth factors.


name: ubiquitin-modified histone reader activity

description: A molecular adaptor that recognizes and binds a histone protein containing a ubiquitination modification and that brings the target protein into contact with another protein to allow those proteins to function in a coordinated way.


Toll binding

description: Binding to a Toll protein, a transmembrane receptor.


chemokine (C-C motif) ligand 19 binding

description: Binding to chemokine (C-C motif) ligand 19.


POU domain binding

description: Binding to a POU domain of a protein. The POU domain is a bipartite DNA binding domain composed of two subunits separated by a non-conserved region of 15-55 amino acids; it is found in several eukaryotic transcription factors.


name: C5a anaphylatoxin chemotactic receptor binding

description: Binding to a C5a anaphylatoxin chemotactic receptor.


name: Edg-3 sphingosine 1-phosphate receptor binding

description: Binding to an Edg-3 sphingosine 1-phosphate receptor.


name: TFIIF-class transcription factor complex binding

description: Binding to a general RNA polymerase II transcription factor belonging to the TFIIF complex, one of the factors involved in formation of the preinitiation complex (PIC) by RNA polymerase II.


name: type 8 metabotropic glutamate receptor binding

description: Binding to a type 8 metabotropic glutamate receptor.


name: eukaryotic initiation factor eIF2 binding

description: Binding to eukaryotic initiation factor eIF2, a protein complex involved in the initiation of ribosome-mediated translation.


name: type 3 proteinase activated receptor binding

description: Binding to a type 3 proteinase activated receptor.


H4 histamine receptor binding

description: Binding to a H4 histamine receptor.


type 5 neuropeptide Y receptor binding

description: Binding to a type 5 neuropeptide Y receptor.


name: growth hormone-releasing hormone receptor binding

description: Binding to a growth hormone-releasing hormone receptor.


RIG-I binding

description: Binding to RIG-I, a cytosolic pattern recognition receptor that initiates an antiviral signaling pathway upon binding to viral RNA.


name: C5L2 anaphylatoxin chemotactic receptor binding

description: Binding to a C5L2 anaphylatoxin chemotactic receptor.


phosphorylated histone binding

description: Binding to a histone in which a residue has been modified by phosphorylation.


microtubule lateral binding

description: Binding to the side of a microtubule.


phytochrome binding

description: Binding to a phytochrome.


myosin VI head/neck binding

description: Binding to the head/neck region of a myosin VI heavy chain.


poly-glutamine tract binding

description: Binding to a polyglutamine tract, i.e. a series of consecutive glutamine residues, in a protein.


interleukin-7 binding

description: Binding to interleukin-7.


methylation-dependent protein binding

description: Binding to a protein upon methylation of the target protein.


type 1 member 2 taste receptor binding

description: Binding to a type 1 member 2 taste receptor.


RHG protein domain binding

description: Binding to an RHG (reaper/hid/grimm) domain/motif (AKA iap binding motif).


name: type 2 melanin-concentrating hormone receptor binding

description: Binding to a type 2 melanin-concentrating hormone receptor.


interleukin-12 beta subunit binding

description: Binding to the beta subunit of interleukin-12.


interleukin-3 binding

description: Binding to interleukin-3.


A1 adenosine receptor binding

description: Binding to an A1 adenosine receptor.


FH1 domain binding

description: Binding to a FH1 domain of a protein, a proline-rich domain, usually located in front of a FH2 domain.


type 1F serotonin receptor binding

description: Binding to a type 1F serotonin receptor.


FMN-binding domain binding

description: Binding to the FMN-binding domain of a protein.


H4K20me3 modified histone binding

description: Binding to a histone H4 in which the lysine residue at position 20 has been modified by trimethylation.


myosin I binding

description: Binding to a class I myosin; myosin I heavy chains are single-headed, possess tails of various lengths, and do not self-associate into bipolar filaments.


signaling receptor binding

description: Binding to one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.


name: plastid PEP RNA polymerase core enzyme binding

description: Binding to a bacterial-type plastid PEP RNA polymerase core enzyme, typically consisting of two alpha, one beta, one beta prime, and one double prime subunit.


P2Y1 nucleotide receptor binding

description: Binding to a P2Y1 nucleotide receptor.


type 4 serotonin receptor binding

description: Binding to a type 4 serotonin receptor.


sterol-dependent protein binding

description: Binding to a protein or protein complex in the presence of sterols.


name: high molecular weight kininogen receptor binding

description: Binding to a high molecular weight kininogen receptor.


bone sialoprotein binding

description: Binding to a bone sialoprotein, an extracellular matrix glycoprotein found on the surface of bones and dentin.


glucagon family peptide binding

description: Binding to a member of the glucagon family peptide hormone (e.g. glucagon, glucagon-like peptides, oxyntomodulin, glicentin, ADCYAP1, GHRH, secretin, VIP, GIP).


motilin receptor binding

description: Binding to a motilin receptor.


tachykinin receptor binding

description: Binding to a tachykinin receptor.


phosphopantetheine binding

description: Binding to phosphopantetheine, the vitamin pantetheine 4'-(dihydrogen phosphate).


interleukin-24 binding

description: Binding to interleukin-24.


endothelin A receptor binding

description: Binding to an endothelin A receptor.


neurokinin receptor binding

description: Binding to a neurokinin receptor.


ghrelin receptor binding

description: Binding to a ghrelin receptor.


neuropeptide Y receptor binding

description: Binding to a neuropeptide Y receptor.


delta-type opioid receptor binding

description: Binding to a delta-type opioid receptor.


adipokinetic hormone receptor binding

description: Binding to an adipokinetic hormone receptor. Adipokinetic hormones (AKHs) are peptide hormones that are involved in the mobilization of sugar and lipids from the insect fat body during energy-requiring activities such as flight and locomotion. They also contribute to hemolymph sugar homeostasis.


myosin II tail binding

description: Binding to the tail region of a myosin II heavy chain.


taste receptor binding

description: Binding to a taste receptor.


F-bar domain binding

description: Binding to an F-BAR domain of a protein, a domain of about 60 residues that occurs in a wide range of cytoskeletal proteins.


name: gastrin-releasing peptide receptor binding

description: Binding to a gastrin-releasing peptide receptor.


neurotensin receptor binding

description: Binding to a neurotensin receptor.


nociceptin receptor binding

description: Binding to a nociceptin receptor.


interleukin-5 binding

description: Binding to interleukin-5.


name: type 1 parathyroid hormone receptor binding

description: Binding to a type 1 parathyroid hormone receptor.


name: lutropin-choriogonadotropic hormone receptor binding

description: Binding to a lutropin-choriogonadotropic hormone receptor.


lipoamide binding

description: Binding to lipoamide, the functional form of lipoic acid in which the carboxyl group is attached to protein by an amide linkage to a lysine amino group.


name: type 1 proteinase activated receptor binding

description: Binding to a type 1 proteinase activated receptor.


serpin family protein binding

description: Binding to a member of the serpin protein family (serine protease inhibitors or classified inhibitor family I4). Serpins are a broadly distributed family of protease inhibitors that use a conformational change to inhibit target enzymes. They are central in controlling many important proteolytic cascades. The majority of serpins inhibit serine proteases, but serpins that inhibit caspases and papain-like cysteine proteases have also been identified. Rarely, serpins perform a non-inhibitory function; for example, several human serpins function as hormone transporters and certain serpins function as molecular chaperones or tumor suppressors.


name: ubiquitin-modified protein reader activity

description: A molecular adaptor recognizes and binds a target protein containing a ubiquitination modification and brings the target protein into contact with another protein to allow those proteins to function in a coordinated way.


alpha-latrotoxin receptor binding

description: Binding to an alpha-latrotoxin receptor.


type 1 neuropeptide Y receptor binding

description: Binding to a type 1 neuropeptide Y receptor.


CD154 receptor binding

description: Binding to CD154, a receptor found on the surface of some activated lymphocytes.


deaminase binding

description: Binding to an enzyme that catalyzes the removal of an amino group from a substrate, producing ammonia (NH3).


ganglioside GM3 binding

description: Binding to ganglioside GM3.


torso binding

description: Binding to a torso (tor) protein, a receptor tyrosine kinase.


type 2 orexin receptor binding

description: Binding to a type 2 orexin receptor.


BH4 domain binding

description: Binding to a BH4 protein domain, present in Bcl-2 family members. All anti-apoptotic proteins contain BH1 and BH2 domains; some also contain an additional N-terminal BH4 domain, which is almost never seen in pro-apoptotic proteins. Loss of the BH4 domain can diminish or abrogate anti-apoptotic function or even impart outright death-promoting properties to the protein.


B2 bradykinin receptor binding

description: Binding to a B2 bradykinin receptor.


antisigma factor binding

description: Binding to an antisigma factor, a factor which inhibits the ability of the sigma factor to function as a transcriptional initiator.


kappa-type opioid receptor binding

description: Binding to a kappa-type opioid receptor.


H3K9me3 modified histone binding

description: Binding to a histone H3 in which the lysine residue at position 9 has been modified by trimethylation.


interleukin-16 binding

description: Binding to interleukin-16.


type 1A melatonin receptor binding

description: Binding to a type 1A melatonin receptor.


SET domain binding

description: Binding to a SET domain of a protein. SET domains are named after three Drosophila proteins that contain this domain: Su(var), E(z) and trithorax. SET domains are associated with histone lysine methylation.


high molecular weight kininogen binding

description: Binding to a kininogen of high molecular mass.


TIMP family protein binding

description: Binding to a member of the Tissue inhibitors of metalloproteinases (TIMPs) family. TIMPs are endogenous protein regulators of the matrix metalloproteinase (MMPs) family.


neuromedin B receptor binding

description: Binding to a neuromedin B receptor.


hemoglobin alpha binding

description: Binding to a hemoglobin alpha chain.


type 1 galanin receptor binding

description: Binding to a type 1 galanin receptor.


name: cell adhesive protein binding involved in atrial cardiac muscle cell-AV node cell communication

description: Binding to a protein or protein complex that results in the connection of an atrial cardiomyocyte with an AV node cell and contributes to the communication between the two cells.


RNA polymerase V core binding

description: Binding to RNA polymerase V core enzyme, a multisubunit eukaryotic nuclear RNA polymerase found in plants and involved in production of noncoding transcripts at target loci for silencing.


complement component C3dg binding

description: Binding to a C3dg product of the complement cascade.


small protein activating enzyme binding

description: Binding to a small protein activating enzyme, such as ubiquitin-activating enzyme.


type 2 cannabinoid receptor binding

description: Binding to a type 2 cannabinoid receptor.


CNBH domain intrinsic ligand binding

description: Interacting selectivity and noncovalently with a cyclic nucleotide mimicking protein motif that is part of the same protein. The CNBHD is a domain on KCNH channels that creates a binding pocket on the KCNH channel that resembles the cyclic nucleotide- binding domain on other ion channels. It binds to a peptide motif that is part of the same protein rather than a cyclic nucleotide.


P2Y4 nucleotide receptor binding

description: Binding to a P2Y4 nucleotide receptor.


name: bacterial-type RNA polymerase holo enzyme binding

description: Binding to a component of the basal transcription machinery which is composed of a bacterial-type RNA polymerase core enzyme and a sigma factor, the minimal set of factors required for formation of the preinitiation complex (PIC) by a bacterial-type RNA polymerase.


thyrotropin-releasing hormone binding

description: Binding to thyrotropin-releasing hormone, a tripeptide hormone that stimulates the release of thyroid-stimulating hormone (TSH) and prolactin by the anterior pituitary and it is produced by the hypothalamus and travels across the median eminence to the pituitary via the pituitary portal system.


wishful thinking binding

description: Binding to wishful thinking (Wit), a type II bone morphogenic protein receptor.


name: general transcription initiation factor binding

description: Binding to a general transcription initiation factor, a protein that contributes to transcription start site selection and transcription initiation.


description: Binding to succinate-semialdehyde dehydrogenase.


type 3 somatostatin receptor binding

description: Binding to a type 3 somatostatin receptor.


type-III dockerin domain binding

description: Binding to a type-III dockerin domain of a protein. Type-III dockerin domain is the binding partner of type-III cohesin domain.


substance K receptor binding

description: Binding to a substance K receptor.


calcitonin family binding

description: Binding to a member of the calcitonin family (e.g. adrenomedullin, adrenomedullin 2 (intermedin), amylin, calcitonin and calcitonin gene-related peptides (CGRPs)).


type 5A serotonin receptor binding

description: Binding to a type 5A serotonin receptor.


RNA polymerase III core binding

description: Binding to an RNA polymerase III core enzyme, a multisubunit eukaryotic nuclear RNA polymerase typically composed of seventeen subunits.


FBXO family protein binding

description: Binding to a member of the FBXO protein family. Members of this family have an F-box protein motif of approximately 50 amino acids that functions as a site of protein-protein interaction.


myosin head/neck binding

description: Binding to the head/neck region of a myosin heavy chain.


F-box domain binding

description: Binding to an F-box domain of a protein.


name: type 1 vasoactive intestinal polypeptide receptor binding

description: Binding to a type 1 vasoactive intestinal polypeptide receptor.


interleukin-35 binding

description: Binding to interleukin-35.


RNA polymerase IV core binding

description: Binding to RNA polymerase IV core enzyme, a multisubunit eukaryotic nuclear RNA polymerase found in plants and involved in siRNA production.


name: integrin binding involved in cell-matrix adhesion

description: Any integrin binding that occurs as part of the process of cell-matrix adhesion.


virus coreceptor activity

description: Combining with a virus component, and in cooperation with a nearby primary receptor, initiating a change in cell activity.


FHA domain binding

description: Binding to a FHA domain of a protein. The FHA domain is a phosphopeptide recognition domain found in many regulatory proteins, and consists of approximately 80-100 amino acid residues folded into an 11-stranded beta sandwich.


P2Y9 nucleotide receptor binding

description: Binding to a P2Y9 nucleotide receptor.


splicing factor binding

description: Binding to a protein involved in the process of removing sections of the primary RNA transcript to form the mature form of the RNA.


somatostatin receptor binding

description: Binding to a somatostatin receptor.


name: vasoactive intestinal polypeptide receptor binding

description: Binding to a vasoactive intestinal polypeptide receptor.


type 1E serotonin receptor binding

description: Binding to a type 1E serotonin receptor.


netrin receptor binding

description: Binding to a netrin receptor.


polo box domain specific binding

description: Binding to a polo box domain of a protein. The polo box domain is involved in binding substrates of polo kinases.


myosin I light chain binding

description: Binding to a light chain of a myosin I complex.


type 2 angiotensin receptor binding

description: Binding to a type 2 angiotensin receptor.


H1 histamine receptor binding

description: Binding to a H1 histamine receptor.


A2A adenosine receptor binding

description: Binding to an A2A adenosine receptor.


interleukin-15 binding

description: Binding to interleukin-15.


calcitonin gene-related peptide binding

description: Binding to calcitonin gene-related peptide (CGRP).


MH1 domain binding

description: Binding to a MH1 (MAD homology 1) protein domain. The MH1 domain is found at the amino terminus of MAD related proteins such as Smads and can mediate DNA binding in some proteins. Smads also use the MH1 domain to interact with some transcription factors.


EH domain binding

description: Binding to an EH domain of a protein. The EH stand for Eps15 homology. This was originally identified as a motif present in three copies at the NH2-termini of Eps15 and of the related molecule Eps15R.


ELYC domain binding

description: Binding to a ELYC protein domain. The ELYC domain is an approximately 150 amino acid sequence which contains a highly conserved tetrapeptide sequence, ELYC.


BH2 domain binding

description: Binding to a BH2 protein domain, present in Bcl-2 family members. Proteins that act as inhibitors of apoptosis harbour at least three BH domains: BH1, BH2 and BH3; the BH1 and BH2 domains are found in all death antagonists of the Bcl-2 family but only in one class of death agonists.


chemokine (C-C motif) ligand 2 binding

description: Binding to chemokine (C-C motif) ligand 2.


myosin I head/neck binding

description: Binding to the head/neck region of a myosin I heavy chain.


type II interferon binding

description: Binding to type II interferon, also known as interferon-gamma.


melatonin receptor binding

description: Binding to a melatonin receptor.


beta-endorphin binding

description: Binding to beta-endorphin, a peptide generated by the cleavage of pro-opiomelanocortin.


name: type 2 proteinase activated receptor binding

description: Binding to a type 2 proteinase activated receptor.


name: type 2 cysteinyl leukotriene receptor binding

description: Binding to a type 2 cysteinyl leukotriene receptor.


X11-like protein binding

description: Binding to X11-like protein, a neuron-specific adaptor protein.


type-I dockerin domain binding

description: Binding to a type-I dockerin domain of a protein. Type-I dockerin domain is the binding partner of type-1 cohesin domain.


ubiquitin-like protein reader activity

description: A molecular adaptor that recognizes and binds a target protein containing a ubiquitin-like modification and that brings the target protein into contact with another protein to allow those proteins to function in a coordinated way.


name: Edg-5 sphingosine 1-phosphate receptor binding

description: Binding to an Edg-5 sphingosine 1-phosphate receptor.


name: G protein-coupled nucleotide receptor binding

description: Binding to a G protein-coupled (metabotropic) nucleotide receptor.


name: mono-ADP-D-ribose modification-dependent protein binding

description: Binding to a protein upon mono-ADP-ribosylation of the target protein.


protein binding

description: Binding to a protein.


modification-dependent protein binding

description: Binding to a protein upon post-translation modification of the target protein.


G protein-coupled GABA receptor binding

description: Binding to a G protein-coupled (metabotropic) GABA receptor.


disordered domain specific binding

description: Binding to a disordered domain of a protein.


Cacosmia

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: A hallucination of an unpleasant odor.


aminodiol

An amino alcohol having two hydroxy functional groups.


name: protein insertion into ER membrane by stop-transfer membrane-anchor sequence

category: biolink:BiologicalProcess biolink:Occurrent biolink:OntologyClass biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing biolink:PhysicalEssenceOrOccurrent

description: A process of protein insertion into the endoplasmic reticulum (ER) membrane in which stop-transfer membrane-anchor sequences become an ER membrane spanning helix.


name: negative regulation of cellular response to amino acid starvation

description: Any process that stops, prevents or reduces the frequency, rate or extent of a cellular response to amino acid starvation.


name: chronic lymphocytic leukemia/small lymphocytic lymphoma

description: An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.


hairy cell leukemia

description: Hairy cell leukemia (HCL) is a rare type of leukemia in which abnormal B-lymphocytes are present in the bone marrow, spleen and peripheral blood. It is a slowly progressive chronic lymphocytic leukemia (CLL). The name comes from the abnormally shaped lymphocytes with hair-like projections.


name: intrapelvic lymph node leukemic reticuloendotheliosis


refractory hairy cell leukemia

description: Hairy cell leukemia that is resistant to treatment.


name: pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma

description: A recently recognized variant of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that lacks somatic hypermutations of the Immunoglobulin heavy chain (IGH) genes, implying pregerminal center B-cell origin. Microarray gene expression profiling studies have demonstrated the expression of ZAP-70 gene (Syk family tyrosine kinase) in this subset of CLL/CLL. Patients with this variant of CLL/SLL have an unfavorable prognosis compared to those with somatic hypermutations of the IGH genes, with a median survival of approximately 6-8 years.


name: chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation

description: A recently recognized variant of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) expressing somatic hypermutations of the Immunoglobulin heavy chain (IGH) genes. The recognition of this variant alters the belief that CLL/SLL is always derived from a naive, pregerminal center B-cell. The presence of somatic hypermutations of IGH genes occurs in approximately 50% of CLL/SLL cases and implies a postgerminal center, memory origin. Patients with this variant of CLL/SLL have a favorable prognosis, with a reported median survival of more than 24 years.


hairy cell leukemia variant

description: Hairy Cell Leukemia variant (HCL-V) is defined as a rare and indolent form of small, mature, B-cell leukemia characterized by splenomegaly, an elevated white blood cell (WBC) count and hyper-cellular bone marrow. HCL-V is more aggressive and resistant to therapy than classical HCL (HCL-C).


superior mesenteric vein

category: biolink:GrossAnatomicalStructure biolink:AnatomicalEntity biolink:PhysicalEssence biolink:OrganismalEntity biolink:SubjectOfInvestigation biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing biolink:PhysicalEssenceOrOccurrent

description: In anatomy, the superior mesenteric vein (SMV) is a blood vessel that drains blood from the small intestine. At its termination behind the neck of the pancreas, the SMV combines with the splenic vein to form the hepatic portal vein. The SMV lies to the right of the similarly named artery, the superior mesenteric artery, which originates from the abdominal aorta. [WP,unvetted].


name: Breast Classic Lobular Carcinoma In Situ Type B

description: Breast classic lobular carcinoma in situ  characterized by the presence of neoplastic cells with nuclei of various sizes and shapes.


name: Early Stage HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that has not spread beyond the breast and the axillary lymph nodes.


name: Prognostic Stage IIIA Breast Cancer AJCC v8

description: Stage IIIA includes: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); ( T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Breast Ductal Carcinoma In Situ and Invasive Lobular Carcinoma

description: A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an invasive lobular carcinomatous component.


Localized Breast Carcinoma

description: Breast carcinoma that is confined to the site in which it initially manifested without evidence of spread to other anatomic sites.


Invasive Breast Cribriform Carcinoma

description: An invasive adenocarcinoma of the breast with a favorable clinical outcome, characterized by the presence of a sieve-like or cribriform infiltrating pattern.


name: Intraductal Micropapillary Breast Carcinoma

description: Breast ductal carcinoma in situ characterized by the presence of neoplastic epithelial cells arranged in micropapillary patterns.


name: Solid papillary carcinoma in situ of breast

description: Breast solid papillary carcinoma characterized by the presence of nodules with rounded, well-circumscribed contours and a distribution pattern consistent with an in situ process. (WHO 2019)


Stage IIA Breast Carcinoma

description: Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)


Stage IIIC Breast Cancer AJCC v7

description: Stage IIIC includes: Any T, N3, M0.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


name: Recurrent Hormone Receptor-Negative Breast Carcinoma

description: The reemergence of hormone receptor-negative breast carcinoma after a period of remission.


breast angiosarcoma

description: A malignant vascular neoplasm arising from the breast.


name: Invasive Breast Lobular Carcinoma, Solid Variant

description: A grade I invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells that form trabeculae and groups infiltrating collagen bundles.


name: Metastatic Triple-Negative Breast Carcinoma

description: A triple-negative breast carcinoma that has spread from its original site of growth to another anatomic site.


name: Invasive Breast Lobular Carcinoma with Predominant In Situ Component

description: A breast carcinoma characterized by the presence of a predominant lobular carcinoma in situ component and a minor component of invasive carcinoma.


Recurrent Malignant Breast Neoplasm

description: The reemergence of a malignant breast neoplasm after a period of remission.


name: Invasive Breast Lobular Carcinoma, Alveolar Variant

description: A grade I invasive lobular carcinoma of the breast, characterized by the presence of round groups of neoplastic cells.


Hereditary Female Breast Carcinoma

description: Breast carcinoma that has developed in female relatives of patients with history of breast carcinoma.


name: High Grade Ductal Breast Carcinoma In Situ

description: Breast ductal carcinoma in situ characterized by the presence of neoplastic cells with severe dysplasia and the formation of micropapillary, cribriform, or solid patterns. The nuclei show marked pleomorphism and have prominent nucleoli. Mitotic activity is usually present. There is comedo-type of necrosis present in the ducts. The necrotic debris is surrounded by pleomorphic malignant cells.


name: Breast Carcinoma Metastatic in the Liver

description: A carcinoma that originates from the breast and has spread to the liver.


name: Unresectable HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that is not amenable to surgical resection.


Recurrent Breast Mucinous Carcinoma

description: The reemergence of breast mucinous carcinoma after a period of remission.


Histiocytoid Breast Carcinoma

description: A rare variant of invasive lobular breast carcinoma characterized by the presence of histiocyte-like malignant cells with pale cytoplasm forming sheets or linear patterns. Apocrine differentiation may be present. It usually has an aggressive clinical course.


name: Squamous Cell Carcinoma In Situ of the Nipple

description: An intraepidermal squamous cell carcinoma involving the area of the nipple.


malignant neoplasm of breast stage I

description: Stage I includes: IA: T1, N0, M0 and IB: (T0, N1mi, M0); (T1, N1mi, M0).  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  T0: No evidence of primary tumor.  N0: No regional lymph node metastasis.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


name: Prognostic Stage 0 Breast Cancer AJCC v8

description: Stage 0 includes: Tis, N0, M0, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Locally Recurrent Breast Carcinoma

description: The reemergence of breast carcinoma after a period of remission, at or adjacent to the site of the original tumor.


name: Refractory HER2-Positive Breast Carcinoma

description: HER2-positive breast carcinoma that is resistant to treatment.


name: Invasive Breast Solid Papillary Carcinoma

description: Breast solid papillary carcinoma associated with areas featuring strands or large clusters of tumor cells. (WHO 2019)


Breast Florid Lobular Carcinoma In Situ

description: Breast lobular carcinoma in situ characterized by the presence of neoplastic cells with cytological features identical to classic lobular carcinoma in situ, but with marked distention of terminal ductal lobular units or ducts.


name: adenocarcinoma of breast with neuroendocrine differentiation

description: An invasive breast carcinoma characterized by the presence of focal neuroendocrine differentiation.


name: Metastatic Breast Inflammatory Carcinoma

description: Inflammatory carcinoma of the breast that has spread from its original site of growth to another anatomic site.


name: Metastatic Breast Neuroendocrine Tumor G1

description: A well differentiated neuroendocrine tumor that arises from the breast and has metastasized to other anatomic sites.


Stage IV Breast Cancer AJCC v6 and v7

description: Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis. (AJCC 6th and 7th Eds.)


name: Unresectable Hormone Receptor-Negative Breast Carcinoma

description: Hormone receptor-negative breast carcinoma that is not amenable to surgical resection.


name: Breast Classic Lobular Carcinoma In Situ

description: Breast lobular carcinoma in situ characterized by the presence of dyscohesive proliferations of type A and/or type B epithelial cells. Type A cells are small cells with uniform hyperchromatic nuclei, whereas type B cells have slightly larger vesicular nuclei, with mild variability in size and shape and with small nucleoli. The cell populations may be mixed in individual proliferations. (WHO 2019)


Atypical Medullary Breast Carcinoma

description: An invasive ductal breast carcinoma characterized by the presence of a predominantly syncytial architectural pattern. It may have some, but not all the strictly defined additional morphologic criteria which are necessary for the diagnosis of medullary breast carcinoma (presence of a diffuse lymphoplasmacytic infiltrate, neoplastic round cells with abundant cytoplasm and vesicular nuclei, complete histological circumscription, and absence of glandular or tubular structures). It does not have the relatively favorable outcome that characterizes medullary breast carcinoma.


name: Refractory Hormone Receptor-Negative Breast Carcinoma

description: Hormone receptor-negative breast carcinoma that is resistant to treatment.


Breast Periductal Stromal Tumor

description: A rare, low-grade malignant stromal tumor that arises from the breast. It is characterized by the proliferation of atypical stromal spindle cells that surround benign tubules and ducts in a pericanalicular pattern. Mitotic activity is present. The tumor has a multinodular and infiltrative growth pattern and lacks the leaf-like architecture of phyllodes tumor. Wide excision with negative margins is the treatment of choice.


Primary angiosarcoma of breast

description: An angiosarcoma that arises from the breast parenchyma and is not associated with radiation exposure.


name: Metastatic HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that has spread to another anatomic site.


name: Recurrent HER2-Positive Breast Carcinoma

description: The reemergence of HER2-positive breast carcinoma after a period of remission.


Anatomic Stage 0 Breast Cancer AJCC v8

description: Stage 0 includes: Tis, N0, M0. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Stage IIIC Breast Cancer AJCC v6

description: Stage IIIC Breast Cancer was added in the 6th Edition AJCC Staging Manual, on the basis of metastasis to the infraclavicular lymph nodes (N3) plus any T, M0.


name: Hormone Receptor-Positive Breast Carcinoma

description: Breast adenocarcinoma that is positive for hormone receptors.


name: Refractory Hormone Receptor-Positive Breast Carcinoma

description: Hormone receptor-positive breast adenocarcinoma that does not respond to treatment.


breast leiomyosarcoma

description: An aggressive malignant smooth muscle neoplasm, arising from the breast. It is characterized by a proliferation of neoplastic spindle cells.


Malignant nipple neoplasm male

description: A malignant neoplasm that affects the area of the nipple in males.


name: Metastatic Breast Neuroendocrine Neoplasm

description: A neuroendocrine neoplasm that arises from the breast and has metastasized to another anatomic site.


name: Inflammatory carcinoma of breast stage III

description: Inflammatory breast carcinoma is classified as AJCC Stage IIIB (T4d) unless other criteria indicate more advanced staging.


name: High Grade Breast Mucoepidermoid Carcinoma

description: An aggressive mucoepidermoid carcinoma that arises from the breast. It is characterized by the presence of focal necrosis and high mitotic activity. Lymph node and distant metastases are common. The prognosis is usually poor.


Postradiation Breast Angiosarcoma

description: A malignant vascular neoplasm arising from the skin of the breast secondary to radiation treatment for breast cancer.


name: Progesterone Receptor-Positive Breast Carcinoma

description: Breast adenocarcinoma that is positive for progesterone receptors.


name: Invasive Breast Ductal Carcinoma and Invasive Lobular Carcinoma

description: An invasive ductal breast carcinoma associated with an invasive lobular carcinomatous component.


name: Metastatic Estrogen Receptor-Positive Breast Carcinoma

description: Estrogen receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Multicentric Breast Carcinoma

description: A breast carcinoma characterized by the presence of multiple cancerous tumors that originate from different clones and are usually located in different quadrants of the breast.


name: Breast Cancer by AJCC v8 Prognostic Stage

description: A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)


Stage IIIB Breast Carcinoma

description: Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N0: No regional lymph node metastasis.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


name: Locally Advanced HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Prognostic Stage IIB Breast Cancer AJCC v8

description: Stage IIB includes: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Invasive Male Breast Carcinoma

description: A rare invasive carcinoma that arises from the male breast. Morphologically, it is similar to the invasive carcinomas that arise from the female breast. It usually develops in the retroareolar region.


Anatomic Stage II Breast Cancer AJCC v8

description: Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0); IIB: (T2, N1, M0); (T3, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Low Grade Breast Adenosquamous Carcinoma

description: A low grade metaplastic carcinoma of the breast with morphologic features similar to the adenosquamous carcinoma of the skin.  In the majority of cases the prognosis is excellent.


name: Refractory Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that is resistant to treatment.


name: Noninfiltrating intraductal papillary adenocarcinoma (morphologic abnormality)

description: Breast ductal carcinoma in situ characterized by the presence of filiform arborizing fibrovascular cores lined by neoplastic ductal epithelium. (WHO 2019)


HER2-Low Breast Carcinoma

description: A breast adenocarcinoma defined by low expression of HER2 (IHC1+ or IHC2+; FISH negative).


name: Metastatic Breast Signet Ring Cell Carcinoma

description: A signet ring cell carcinoma that arises from the breast and has metastasized to other anatomic sites.


Breast adenocarcinoma metastatic

description: An adenocarcinoma that arises from the breast and has metastasized to another anatomic site.


name: Recurrent Estrogen Receptor-Positive Breast Carcinoma

description: The reemergence of estrogen receptor-positive breast carcinoma after a period of remission.


Stage II Breast Cancer AJCC v6 and v7

description: Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, M0); (T3, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 2.0 cm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension.  T3: Tumor more than 5.0 cm in greatest dimension.  N1: Metastasis to movable ipsilateral axillary lymph node(s).  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


name: Inflammatory carcinoma of breast recurrent

description: The reemergence of inflammatory carcinoma of the breast after a period of remission


name: Breast Carcinoma with Choriocarcinomatous Features

description: An invasive ductal breast carcinoma, not otherwise specified, characterized by increased levels of human beta-chorionic gonadotropin in the serum.  Morphologic evidence of choriocarcinomatous differentiation is rare.


name: Prognostic Stage II Breast Cancer AJCC v8

description: Stage II includes: IIA: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIB: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Carcinoma in situ of female breast

description: A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the female breast.


name: Intraductal papillary adenocarcinoma with invasion

description: A carcinoma that has papillary growth and invades the wall and/or the surrounding tissues of the organ it originates from.


Recurrent Breast Angiosarcoma

description: The reemergence of breast angiosarcoma after a period of remission.


name: Anatomic Stage IIA Breast Cancer AJCC v8

description: Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Malignant neoplasm of nipple of female breast

description: A malignant neoplasm that affects the area of the nipple in females.


name: Paget's disease and infiltrating duct carcinoma of breast

description: Paget disease involving the skin overlying the mammary gland, accompanied by invasive ductal breast carcinoma.


Anatomic Stage IA Breast Cancer AJCC v8

description: Stage IA includes: T1, N0, M0. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Recurrent Breast Medullary Carcinoma

description: The reemergence of breast medullary carcinoma after a period of remission.


name: Invasive Breast Lobular Carcinoma, Tubulolobular Variant

description: An invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells forming small tubular structures.


name: Hormone Receptor-Negative Breast Carcinoma

description: Breast adenocarcinoma that is negative for hormone receptors.


name: Locally Advanced Estrogen Receptor-Positive Breast Carcinoma

description: Estrogen receptor-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Breast sarcoma recurrent

description: The reemergence of breast sarcoma after a period of remission.


name: Breast Carcinoma with Osseous Metaplasia

description: An invasive breast carcinoma showing differentiation towards bone structures.


Breast Polymorphous Adenocarcinoma

description: A rare, low grade malignant epithelial neoplasm arising from the breast. It is characterized by the presence of uniform, small to medium size malignant epithelial cells and an infiltrating pattern.


Stage III Breast Cancer AJCC v7

description: Stage III includes: IIIA : (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0), IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0), and IIIC: (any T, N3, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


BRCA-Associated Breast Carcinoma

description: Breast carcinoma caused by deleterious germline mutation in a gene of the BRCA family.


name: Unresectable Hormone Receptor-Positive Breast Carcinoma

description: Hormone receptor-positive breast carcinoma that is not amenable to surgical resection.


name: Invasive Breast Carcinoma of No Special Type with Predominant Intraductal Component

description: An invasive breast carcinoma of no special type characterized by the presence of a predominant ductal carcinoma in situ component and a minor component of invasive carcinoma.


name: Prognostic Stage IA Breast Cancer AJCC v8

description: Stage IA includes: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Pleomorphic lobular carcinoma in situ of breast

description: Breast lobular carcinoma in situ characterized by the presence of neoplastic large cells with marked nuclear pleomorphism.


name: Invasive micropapillary carcinoma of breast

description: An invasive breast carcinoma characterized by the presence of clusters of malignant cells located within artifactual clear stromal spaces that resemble vascular spaces.


name: Anatomic Stage IIIB Breast Cancer AJCC v8

description: Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Unilateral Breast Carcinoma

description: Breast carcinoma of one breast, or one side of the breast.


Childhood Malignant Breast Neoplasm

description: A malignant neoplasm that affects the breast and occurs during childhood.


Carcinoma in situ of male breast

description: A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the male breast. It includes the entire spectrum of carcinoma in situ observed in the female breast. It usually develops in the retroareolar region.


name: Paget's disease and intraductal carcinoma of breast

description: Paget disease of the breast associated with the presence of a usually high grade ductal carcinoma in situ in the lactiferous glands.


Stage III Breast Cancer AJCC v6

description: Stage III is divided into two stages IIIA and IIIB.  Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  Stage IIIB includes: (T4, any N, M0).  T4: Tumor of any size with direct extension to (a) chest wall or (b) skin.  N2: Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis.  N3: Metastasis in ipsilateral infraclavicular lymph nodes(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph node(s); and in the presence of clinically evident axillary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No distant metastasis.  (AJCC 6th Ed.)


Metastatic Breast Lobular Carcinoma

description: A lobular breast carcinoma that has spread from the original site of growth to another anatomic site.


Refractory Breast Adenocarcinoma

description: Breast adenocarcinoma that does not respond to treatment.


name: Invasive Breast Carcinoma by Histologic Grade


Unresectable Breast Carcinoma

description: Breast carcinoma that is not amenable to surgical resection.


name: Recurrent HER2-Negative Breast Carcinoma

description: The reemergence of HER2-negative breast adenocarcinoma after a period of remission.


Breast adenocarcinoma recurrent

description: The reemergence of breast adenocarcinoma after a period of remission.


name: Locally Advanced HER2-Low Breast Carcinoma

description: A HER2-low breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


PALB2-Associated Breast Carcinoma

description: Breast carcinoma caused by deleterious germline mutation in the PALB2 gene.


name: Recurrent Invasive Breast Carcinoma of No Special Type

description: The reemergence of invasive breast carcinoma of no special type after a period of remission.


Metastatic Breast Carcinoma

description: A carcinoma that arises from the breast and has metastasized to another anatomic site.


Refractory Breast Lymphoma

description: Breast lymphoma that is resistant to treatment.


name: Breast Ductal Carcinoma In Situ, Comedo Type

description: Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells with evidence of central necrosis and associated karyorrhectic/nuclear debris.


Occult Breast Carcinoma

description: Breast carcinoma presenting with isolated axillary lymphadenopathy, without clinical or mammographic evidence of breast tumor.


name: Prognostic Stage III Breast Cancer AJCC v8

description: Stage III includes: IIIA: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIIB: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); IIIC: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: solid type ductal carcinoma in situ of breast

description: Breast ductal carcinoma in situ in which the tumor cells fill the ductal spaces as solid sheets.


Malignant nipple neoplasm

description: A malignant neoplasm that affects the area of the nipple.


Recurrent Breast Papillary Carcinoma

description: The reemergence of breast papillary carcinoma after a period of remission.


breast liposarcoma

description: A malignant adipose tissue neoplasm of the breast.


name: Prognostic Stage IV Breast Cancer AJCC v8

description: Stage IV includes: Any T, Any N, M1, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)


name: Metastatic Androgen Receptor-Positive Breast Carcinoma

description: Androgen receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


breast sarcoma

description: A malignant mesenchymal neoplasm that arises from the breast. Representative examples include angiosarcoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, and extraskeletal osteosarcoma.


Breast Carcinoma Metastatic in the Lung

description: A carcinoma that arises from the breast and has metastasized to the lung.


Invasive Breast Apocrine Carcinoma

description: An invasive breast adenocarcinoma with cytological and immunophenotypic characteristics of apocrine differentiation in more than 90 percent of the malignant cells.


name: Anatomic Stage IIIC Breast Cancer AJCC v8

description: Stage IIIC includes: Any T, N3, M0. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Metastatic Triple-Negative Breast Inflammatory Carcinoma

description: Triple-negative breast inflammatory carcinoma that has spread from its original site of growth to another anatomic site.


Carcinoma breast stage I

description: Stage 1 includes T1, NO, MO.  T1: Tumor 2.0 cm or less in greatest dimension.  T1mic: Microinvasion 0.1 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th Ed.)-2003


name: Breast Tall Cell Carcinoma with Reversed Polarity

description: A rare subtype of invasive breast carcinoma characterized by tall columnar cells with reversed nuclear polarity, arranged in solid and solid papillary patterns, most commonly associated with IDH2 p.Arg172 hotspot mutations. (WHO 2019)


name: Androgen Receptor-Positive Breast Carcinoma

description: Breast carcinoma that is positive for androgen receptors.


name: Synchronous Ipsilateral Breast Carcinoma

description: Diagnosis of more than one distinct tumor focus in the same breast, within two months.


name: Resectable Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that is amenable to surgical resection.


name: Prognostic Stage IIIC Breast Cancer AJCC v8

description: Stage IIIC includes: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Anatomic Stage IIB Breast Cancer AJCC v8

description: Stage IIB includes: (T2, N1, M0); (T3, N0, M0). T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Grade 1 Invasive Breast Carcinoma

description: A well differentiated invasive breast carcinoma.


name: Unresectable HER2-Positive Breast Carcinoma

description: HER2-positive breast carcinoma that is not amenable to surgical resection.


Secondary malignant neoplasm of breast

description: The spread of a malignant neoplasm to the breast. This may be from a primary breast malignant neoplasm on the opposite side, or from a malignant neoplasm at a distant site.


Grade 3 Invasive Breast Carcinoma

description: A poorly differentiated invasive breast carcinoma.


name: Unresectable Estrogen Receptor-Positive Breast Carcinoma

description: Estrogen receptor-positive breast carcinoma that is not amenable to surgical resection.


Stage IB Breast Cancer AJCC v7

description: Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


breast rhabdomyosarcoma

description: A malignant mesenchymal tumor with skeletal muscle differentiation affecting the breast.


Breast Cancer by AJCC v7 Stage

description: A term that refers to the staging of breast cancer according to the American Joint Committee on Cancer, 7th edition.


Stage IIB Breast Carcinoma

description: Stage IIB includes: (T2, N1, M0); (T3, N0, M0).  T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  T3: Tumor more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)


Anatomic Stage IB Breast Cancer AJCC v8

description: Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Breast Ductal Carcinoma In Situ and Lobular Carcinoma

description: A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an in situ or invasive lobular carcinomatous component.


breast extraskeletal osteosarcoma

description: An osteosarcoma arising from the breast tissue.


name: Recurrent Breast Ductal Carcinoma In Situ

description: The reemergence of breast ductal carcinoma in situ after a period of remission.


name: Breast Ductal Carcinoma In Situ, Non-Comedo Type

description: Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells without evidence of central necrosis or cell death.


name: Locally Advanced Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Invasive Breast Lobular Carcinoma, Signet Ring Variant

description: An invasive lobular carcinoma characterized by the presence of malignant epithelial cells with large intracytoplasmic lumina that cause displacement of the nuclei towards one pole of the cells.


name: Prognostic Stage I Breast Cancer AJCC v8

description: Stage I includes: IA: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any); IB: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)